This resource provides Good Manufacturing Practice (GMP)-quality candidate vaccine viruses for zoonotic influenza, a critical component of global influenza pandemic preparedness. Candidate vaccine viruses have been used to create H5, H9, and H7 vaccine lots that have been deployed to national stockpiles and/or clinical trials.

The WRCEVA program maintains the Emerging Viruses and Arboviruses Reference Collection and provides reagents and support for investigations of virus outbreaks throughout the world. 

The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

The Schistosomiasis Resource Center (SRC) provides three major strains of snails (Biomphalaria glabrata, Bulinus truncatus, and Oncomelania hupensis) and rodents infected with S. haematobium, S. japonicum, and S.mansoni. Molecular reagents include nucleic acids and genomic libraries from the various life cycle stages of the Schistosoma species (cercariae, schistosomula, adult worms and eggs).

The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, carried out in an expeditious and efficient manner, aided by bioanalysis when necessary, against viral, bacterial, parasitic, and fungal pathogens and emerging and re-emerging infectious diseases. The candidate products assessed through the EPCTUs may include licensed or investigational products such as small molecules, monoclonal antibodies, i

Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

Note: Devices are excluded.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

The Filariasis Research Reagent Resource Center (FR3) maintains oversight of filarial parasites, SOPs, and molecular reagents. FR3 is comprised of two divisions: The Parasite Resource Division and the Molecular Resources Division.

Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

The ARLG biorepositories were created to aid in the development and evaluation of novel diagnostic tests and laboratory techniques, study mechanisms of resistance, generate preliminary data for study concepts, and support/mentor early-stage investigators pursuing research in the field of antibacterial resistance.